Notis-mcconarty Edward Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Notis-mcconarty Edward reduced its stake in Merck & Co. by 0.48% during the most recent quarter end. The investment management company now holds a total of 20,555 shares of Merck & Co. which is valued at $1.2 Million after selling 100 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 27, 2016.Merck & Co. makes up approximately 0.81% of Notis-mcconarty Edward’s portfolio.

Other Hedge Funds, Including , Hm Payson Co boosted its stake in MRK in the latest quarter, The investment management firm added 14,419 additional shares and now holds a total of 345,154 shares of Merck & Co. which is valued at $19 Million. Merck & Co. makes up approx 0.99% of Hm Payson Co’s portfolio.Waters Parkerson boosted its stake in MRK in the latest quarter, The investment management firm added 10,629 additional shares and now holds a total of 285,311 shares of Merck & Co. which is valued at $15.7 Million. Merck & Co. makes up approx 1.69% of Waters Parkerson’s portfolio.Piedmont Investment Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 7,135 additional shares and now holds a total of 774,898 shares of Merck & Co. which is valued at $41.8 Million. Merck & Co. makes up approx 0.89% of Piedmont Investment Advisors’s portfolio.

Merck & Co. closed down -0.17 points or -0.30% at $57 with 62,52,365 shares getting traded on Tuesday. Post opening the session at $57.2, the shares hit an intraday low of $56.92 and an intraday high of $57.44 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Investors should note that on May 24, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Jun 13, 2016 as the ex-dividend date and fixed the record date on Jun 15, 2016. The payable date has been fixed on Jul 8, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.